CRISPR/Cas13: A potential therapeutic option of COVID-19 - 28/10/20
Graphical abstract |
Highlights |
• | The novel coronavirus disease (COVID-19) is a global issue. |
• | CRISPR/Cas13 is a potential diagnostic method of COVID-19. |
• | CRISPR/Cas13 and CRISPR/deadCas13 are the potential therapeutic candidates of COVID-19. |
Abstract |
The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world. Although scientists are trying to discover novel therapies and develop and evaluate various previous treatments, at the time of writing this paper, there was no definite therapy and vaccine for COVID-19. So, as COVID-19 has called ideas for treatment, controlling, and diagnosis, we discussed the application of Clustered Regularly Interspaced Short Palindromic Repeats/Cas13 (CRISPR/Cas13) as a treatment of COVID-19, which received less attention compared with other potential therapeutic options.
Le texte complet de cet article est disponible en PDF.Keywords : CRISPR/Cas13, CRISPR/dead Cas13, COVID-19, SARS-CoV-2, Treatment
Plan
Vol 131
Article 110738- novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.